A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence
- 1 September 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 56 (9), 1067-1081
- https://doi.org/10.1211/0022357044265
Abstract
It is assumed that proteins from the ABC family (i.e., glycoprotein P (Pgp)) and a multidrug resistance associated protein (MRP) play a main role in the occurrence of multidrug resistance (MDR) in tumour cells. Other factors that influence the rise of MDR are mechanisms connected with change in the effectiveness of the glutathione cycle and with decrease in expression of topoisomerases I and II. The aim of this review is to characterize drugs applied in anti-tumour therapy and to describe the present state of knowledge concerning the mechanisms of MDR occurrence, as well as the pharmacological agents applied in reducing this phenomenon.Keywords
This publication has 152 references indexed in Scilit:
- Classification of anticancer drugs—a new system based on therapeutic targetsCancer Treatment Reviews, 2003
- Structure and biological activity of cationic [PtLCl(DMSO)]NO3·DMSO complex containing a chelated diaminosugar: methyl-3,4-diamino-2,3,4,6-tetradeoxy-α-l-lyxopyranosideEuropean Journal of Medicinal Chemistry, 2003
- MDR1 inhibition: less resistance or less relevance?European Journal Of Cancer, 2002
- Prolonged Wild-Type p53 Protein Accumulation and Cisplatin ResistanceBiochemical and Biophysical Research Communications, 2001
- Cytotoxic Mechanism of XK469: Resistance of Topoisomerase IIβ Knockout Cells and Inhibition of Topoisomerase IBiochemical and Biophysical Research Communications, 2001
- ras mutation and platinum resistance in human ovarian carcinomasin vitroInternational Journal of Cancer, 1998
- Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisersEuropean Journal Of Cancer, 1996
- Glutathione and related enzymes in multidrug resistanceEuropean Journal Of Cancer, 1996
- The role of the MDR protein in altered drug translocation across tumor cell membranesBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1995
- Partial characterization of the DNA repair protein complex, containing the ERCC1, ERCC4, ERCC11 and XPF correcting activitiesMutation Research/DNA Repair, 1995